Recro Pharma, Inc. (REPH) Reaches $8.04 Formed H&S; 12 Analysts Bullish Nutrien Ltd. (POT)

Among 24 analysts covering Potash Corp (NYSE:POT), 12 have Buy rating, 5 Sell and 7 Hold. Therefore 50% are positive. Potash Corp had 73 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Sector Performer” rating by IBC given on Monday, April 4. Vertical Research downgraded the stock to “Hold” rating in Thursday, April 21 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, March 16. Cowen & Co downgraded Nutrien Ltd. (NYSE:POT) on Thursday, April 14 to “Underperform” rating. The stock has “Buy” rating by RBC Capital Markets on Thursday, September 14. The rating was maintained by Raymond James with “Market Perform” on Monday, October 30. RBC Capital Markets maintained Nutrien Ltd. (NYSE:POT) rating on Wednesday, October 21. RBC Capital Markets has “Sector Perform” rating and $24 target. Stifel Nicolaus upgraded the stock to “Buy” rating in Wednesday, September 14 report. The stock has “Neutral” rating by Atlantic Securities on Monday, October 31. The rating was upgraded by HSBC on Tuesday, December 15 to “Buy”. See Nutrien Ltd. (NYSE:POT) latest ratings:

05/12/2017 Broker: Stephens Rating: Overweight Initiates Coverage On
07/11/2017 Broker: BMO Capital Markets Rating: Hold New Target: $17.5 Maintain
03/11/2017 Broker: Cowen & Co Rating: Hold New Target: $19.5 Maintain
30/10/2017 Broker: Raymond James Rating: Market Perform Maintain
27/10/2017 Broker: UBS Rating: Buy Old Target: $21 New Target: $22 Maintain
16/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $20.0 Maintain
10/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $22.0 Maintain
11/10/2017 Broker: HSBC Rating: Buy New Target: $24.25 Initiates Coverage On
05/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $17.5 Maintain
28/09/2017 Broker: TD Securities Old Rating: Hold New Rating: Buy Upgrade

Recro Pharma, Inc. (REPH) formed H&S with $7.72 target or 4.00% below today’s $8.04 share price. Recro Pharma, Inc. (REPH) has $153.78M valuation. The stock decreased 0.50% or $0.04 during the last trading session, reaching $8.04. About 70,009 shares traded. Recro Pharma, Inc. (NASDAQ:REPH) has risen 26.61% since February 9, 2017 and is uptrending. It has outperformed by 9.91% the S&P500.

Since December 12, 2017, it had 0 insider purchases, and 5 sales for $1.43 million activity. On Tuesday, January 2 SCP Vitalife Partners (Israel) II – L.P. sold $115,139 worth of Recro Pharma, Inc. (NASDAQ:REPH) or 12,964 shares. Broadfin Healthcare Master Fund Ltd sold 93,237 shares worth $919,128. SCP Vitalife Partners II LP sold 4,732 shares worth $41,822.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on March, 5. They expect $-0.78 earnings per share, up 3.70% or $0.03 from last year’s $-0.81 per share. After $-0.48 actual earnings per share reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 62.50% negative EPS growth.

Among 8 analysts covering Recro Pharma (NASDAQ:REPH), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 14 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Friday, September 16 by TH Capital. As per Monday, December 19, the company rating was initiated by Piper Jaffray. The stock of Recro Pharma, Inc. (NASDAQ:REPH) has “Buy” rating given on Thursday, July 20 by Roth Capital. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, November 24. The firm has “Buy” rating by Roth Capital given on Monday, July 31. The stock of Recro Pharma, Inc. (NASDAQ:REPH) earned “Buy” rating by Roth Capital on Thursday, November 9. The stock has “Hold” rating by Zacks on Tuesday, August 25. The stock of Recro Pharma, Inc. (NASDAQ:REPH) earned “Buy” rating by Piper Jaffray on Tuesday, July 25. The stock of Recro Pharma, Inc. (NASDAQ:REPH) earned “Buy” rating by H.C. Wainwright on Wednesday, September 2. The firm earned “Buy” rating on Monday, August 29 by Janney Capital.

Investors sentiment decreased to 1.65 in 2017 Q3. Its down 0.56, from 2.21 in 2017Q2. It worsened, as 7 investors sold Recro Pharma, Inc. shares while 10 reduced holdings. 5 funds opened positions while 23 raised stakes. 9.63 million shares or 4.72% less from 10.10 million shares in 2017Q2 were reported. Renaissance Technology Lc has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 98,900 shares. Dimensional Fund Advisors Limited Partnership accumulated 0% or 129,560 shares. California State Teachers Retirement Sys reported 22,400 shares. 259,948 are owned by Kingdon Cap Mgmt Limited Liability Com. California Employees Retirement accumulated 64,300 shares. Jpmorgan Chase And reported 21,784 shares. Rothschild Inv Corp Il reported 25,000 shares. Cadence Capital Management Ltd Liability Com, a Massachusetts-based fund reported 167,637 shares. Moreover, Royal Bancshares Of Canada has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH). Fincl Bank Of New York Mellon Corporation owns 52,391 shares for 0% of their portfolio. Deutsche Fincl Bank Ag has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH). Granite Point Lp stated it has 38,000 shares or 0.07% of all its holdings. Moreover, Advisory Svcs Ntwk Limited Co has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH). Manufacturers Life Insur Com The reported 140 shares stake. Alyeska Invest Gp Lp owns 0.07% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 906,398 shares.